₹ 1,313.05
-25.45 (-1.9%)Open
1349High
1349Low
1300.65Prev Close
1338.5P/E
23.79Median P/E
31.48P/B
5.5Median P/B
4.77Market Cap
99.72BPEG
1.22Div.Yield
0.33Bid
-Ask
-Large Cap
99.72B Mkt. Cap.Volatility
-Beta
0.64Genie Says
Influencer Count
-Days | BSE | NSE |
---|
5 | 1,338.30 | 1,337.92 |
10 | 1,314.61 | 1,314.42 |
20 | 1,319.30 | 1,319.81 |
50 | 1,328.14 | 1,328.45 |
100 | 1,382.70 | 1,383.34 |
300 | 1,230.50 | 1,231.09 |
BSE
524742NSE
CAPLIPOINTISIN
INE475E01026Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
D. Muralidharan
Chief Financial OfficerG. Venkatram
Compliance Officer, General Counsel, Company SecretarySridhar Ganesan
Managing Director, Executive Director